NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing

HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.) NRx continues work to enable the distribution of shares in Hope Therapeutics. This distribution is dependent upon completion of a public audit and successful review of an SEC Form 10. NRX-101 is the Company's patented (Composition of Matter), oral combination of the NMDA antagonist Dcycloserine and lurasidone for bipolar depression. Data from two active control clinical trials vs. the ...